Daphne R Friedman

List of Publications by Year
in descending order

29 papers	383 citations	840776 11 h-index	794594 19 g-index
30 all docs	30 docs citations	30 times ranked	859 citing authors

#	Article	IF	Citations
1	Integration of Patient-Reported Outcome Measures in the Electronic Health Record: The Veterans Affairs Experience. JCO Clinical Cancer Informatics, 2022, 6, e2100086.	2.1	3
2	Identifying and Overcoming Barriers in Clinical Trial Enrollment for Veterans with Blood Cancers. Blood, 2021, 138, 1920-1920.	1.4	0
3	Post-translational regulation could be determine functional differences between <scp>SET</scp> alpha and beta isoform – Response to Cristóbal <i>et al</i>. British Journal of Haematology, 2019, 186, 637-637.	2.5	0
4	<scp>SET</scp> alpha and <scp>SET</scp> beta <scp>mRNA</scp> isoforms in chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 184, 605-615.	2.5	24
5	Partners in Oncology Care: Coordinated Follicular Lymphoma Management. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, S21-S23.	0.6	0
6	Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling. British Journal of Haematology, 2018, 183, 747-754.	2.5	5
7	Lipids and Their Effects in Chronic Lymphocytic Leukemia. EBioMedicine, 2017, 15, 2-3.	6.1	6
8	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. American Journal of Hematology, 2016, 91, 687-691.	4.1	20
9	Perifosine as a potential novel anti-telomerase therapy. Oncotarget, 2015, 6, 21816-21826.	1.8	18
10	Utilization of the <i>Eµ-Myc</i> Mouse to Model Heterogeneity of Therapeutic Response. Molecular Cancer Therapeutics, 2014, 13, 3219-3229.	4.1	19
11	Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and<i>in vitro</i>studies. Leukemia and Lymphoma, 2014, 55, 1067-1075.	1.3	28
12	CD38 variation as a prognostic factor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 191-194.	1.3	11
13	"Primum non nocere" the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 441-442.	1.3	0
14	Clinical and Biological Relevance of Genomic Heterogeneity in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e57356.	2.5	4
15	Comparison of the PI3K-δ Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro. Blood, 2012, 120, 3914-3914.	1.4	5
16	CD38 Variation in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4576-4576.	1.4	0
17	Modeling Variation in the Human Lymphoma Microenvironment with the Eµ-Myc Mouse Model. Blood, 2012, 120, 789-789.	1.4	1
18	SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood, 2011, 118, 4150-4158.	1.4	108

#	Article	IF	Citations
19	Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells. Blood, 2011, 118, 286-286.	1.4	0
20	Genomic Heterogeneity in B-Cell Malignancies,. Blood, 2011, 118, 3465-3465.	1.4	0
21	Informational needs assessment of non‐Hodgkin lymphoma survivors and their physicians. American Journal of Hematology, 2010, 85, 528-532.	4.1	17
22	Statin use and need for therapy in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 2295-2298.	1.3	18
23	Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 1842-1842.	1.4	2
24	A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2009, 15, 6947-6955.	7.0	37
25	Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2344-2344.	1.4	9
26	The Anti-Inflammatory Investigational Agent LMP-420 Demonstrates in Vitro Cytotoxic Activity against Chronic Lymphocytic Leukemia Cells.. Blood, 2009, 114, 2358-2358.	1.4	0
27	A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.. Blood, 2009, 114, 2403-2403.	1.4	0
28	Identification of Therapeutic Targets for Chronic Lymphocytic Leukemia in the Relapsed and Refractory Setting.. Blood, 2008, 112, 2068-2068.	1.4	0
29	Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. American Journal of Hematology, 2007, 82, 1063-1070.	4.1	47